SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-23-008628
Filing Date
2023-03-30
Accepted
2023-03-30 16:15:39
Documents
15
Period of Report
2023-03-30
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K vtgn20230329_8k.htm   iXBRL 8-K 22877
2 EXHIBIT 99.1 ex_494923.htm EX-99.1 26609
7 vistalogo.jpg GRAPHIC 2564
  Complete submission text file 0001437749-23-008628.txt   195132

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vtgn-20230330.xsd EX-101.SCH 3601
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vtgn-20230330_def.xml EX-101.DEF 11532
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE vtgn-20230330_lab.xml EX-101.LAB 15414
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vtgn-20230330_pre.xml EX-101.PRE 11688
9 EXTRACTED XBRL INSTANCE DOCUMENT vtgn20230329_8k_htm.xml XML 2566
Mailing Address 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 650-577-3600
Vistagen Therapeutics, Inc. (Filer) CIK: 0001411685 (see all company filings)

IRS No.: 205093315 | State of Incorp.: NV | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-37761 | Film No.: 23780878
SIC: 2834 Pharmaceutical Preparations